Humacyte, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
Humacyte, Inc. (HUMA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets of $100.00 thousand as of 2021-08-26, per its 10-Q filed 2021-11-15.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets · last filed 2021-11-15
- 2021-08-26: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets $100.00K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets |
|---|---|
| 2021-08-26 | $100.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |